Clinical Trial Update: A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating STRO-002 in combination with bevacizumab for epithelial ovarian cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• STRO-002 (STRO-002)

Snippet

Sponsor: Sutro Biopharma, Inc. | Conditions: Ovarian Cancer, Ovarian Carcinoma | Phase 1 | Status: TERMINATED